Project will create the largest dataset of molecular profiling for
patients with multiple myeloma leading to tests that could improve
diagnosis, prognosis and new treatments
SAN DIEGO -- (Business Wire)
Celgene Corporation (NASDAQ:CELG), Dana-Farber Cancer Institute and the
University of Arkansas for Medical Sciences today announced the creation
of the Myeloma Genome Project, a collaborative initiative aimed at
compiling the largest dataset of high-quality genomic and clinical data
to identify distinct molecular disease segments within multiple myeloma
to advance diagnosis, prognosis and treatment of multiple myeloma
patients. The initiative seeks to develop clinically relevant tests.
Details of the project and initial characterization and preliminary
analyses of newly diagnosed myeloma patient data were presented today by
Brian Walker, Ph.D., of the University of Arkansas for Medical Sciences
at the 58th American Society of Hematology Annual Meeting in
San Diego, Calif.
“The Myeloma Genome Project is a really exciting initiative that may
change the way we manage myeloma patients,” said Gareth Morgan, M.D.,
Ph.D., Director of the Myeloma Institute at the University of Arkansas
for Medical Sciences.
Current technologies have discovered five major translocation groups
within myeloma patients and these mutations have demonstrated varying
effects on prognosis. The Myeloma Genome Project is also looking at
minor translocation and mutational groups that are often poorly
described due to small sample numbers in limited data sets. The group
has established a set of 2,161 patients for which whole exome sequencing
(WES; n=1,436), whole genome sequencing (WGS; n=708), targeted panel
sequencing (n=993) and expression data from RNA-sequencing and gene
expression arrays (n=1,497) were available. The data were collected from
the Myeloma XI trial (UK), Intergroupe Francophone du
Myeloma/Dana-Farber Cancer Institute, Myeloma Institute at the
University of Arkansas for Medical Sciences and the Multiple Myeloma
Research Foundation.
“Understanding the various subgroups within multiple myeloma that
exhibit distinct pathogenesis and clinical behavior is critical when
looking to advance new therapies, particularly when considering a
targeted approach,” said Rob Hershberg, M.D., Ph.D., Executive Vice
President and Chief Scientific Officer at Celgene. “We look forward to
the insights that this collaboration will provide for research and for
patients.”
“The Myeloma Genome Project expects to lead the way towards developing
personalized and targeted therapy to improve patient outcomes in
myeloma,” said Nikhil Munshi, M.D., Director of Basic and Correlative
Science at the Jerome Lipper Multiple Myeloma Center at Dana-Farber
Cancer Institute.
The Myeloma Genome Project has begun to integrate these diverse, large
genomic data sets and is identifying genetic information that may inform
clinical targets for therapy. While analyses are not completed, the
current efforts clearly demonstrate the feasibility of this approach and
the project leaders plan to expand collaboration to include additional
investigators and institutions and present updates at future medical and
scientific meetings including publications in peer-reviewed journals.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
Pinterest,
LinkedIn,
Facebook
and YouTube.
About Dana-Farber Cancer Institute
From achieving the first remissions in childhood cancer with
chemotherapy in 1948, to developing the very latest new therapies,
Dana-Farber Cancer Institute is one of the world’s leading centers of
cancer research and treatment. It is the only center ranked in the top 4
of U.S. News and World Report’s Best Hospitals for both adult and
pediatric cancer care.
Dana-Farber sits at the center of a wide range of collaborative efforts
to reduce the burden of cancer through scientific inquiry, clinical
care, education, community engagement, and advocacy. Dana-Farber/Brigham
and Women’s Cancer Center provides the latest in cancer care for adults;
Dana-Farber/Boston Children's Cancer and Blood Disorders Center for
children. The Dana-Farber/Harvard Cancer Center unites the cancer
research efforts of five Harvard academic medical centers and two
graduate schools, while Dana-Farber Community Cancer Care provides high
quality cancer treatment in communities outside Boston’s Longwood
Medical Area.
Dana-Farber is dedicated to a unique, 50/50 balance between cancer
research and care, and much of the Institute’s work is dedicated to
translating the results of its discovery into new treatments for
patients locally and around the world.
About the University of Arkansas for Medical Sciences
The University of Arkansas for Medical Sciences (UAMS) is Arkansas’ only
comprehensive academic health center, with colleges of Medicine,
Nursing, Pharmacy, Health Professions and Public Health; a graduate
school; a hospital; a northwest Arkansas regional campus; a statewide
network of regional centers; and seven institutes: the Winthrop P.
Rockefeller Cancer Institute, the Jackson T. Stephens Spine &
Neurosciences Institute, the Myeloma Institute, the Harvey & Bernice
Jones Eye Institute, the Psychiatric Research Institute, the Donald W.
Reynolds Institute on Aging and the Translational Research Institute. It
is the only adult Level 1 trauma center in Arkansas. UAMS physicians and
other professionals provide care to patients at UAMS, Arkansas
Children’s Hospital, the VA Medical Center and UAMS regional centers
throughout the state. The UAMS Myeloma Institute is the most
comprehensive center in the world for research and clinical care
related to multiple myeloma and related diseases, such as Castleman
Disease and Waldenstrom Macroglobulemia. The institute’s
team of scientists and clinicians has pioneered many advances that have
become standards of care, leading to improved survival rates. The UAMS
Myeloma Institute is known for its “bench to bedside” approach,
continually translating advances in the laboratory into breakthrough
clinical treatments.
Visit www.uams.edu
or www.uamshealth.com.
Find us on Facebook,
Twitter,
YouTube
or Instagram.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161203005056/en/
Contacts:
Media:
For Celgene:
Greg Geissman, +1-908-673-9854
Senior
Director, Corporate Affairs Communications
ggeissman@celgene.com
or
For
UAMS:
Leslie Taylor, +1-501-951-7260
Vice Chancellor,
Communications & Marketing
leslie@uams.edu
or
For
DFCI:
Ellen Berlin, +1-617-632-5357
Director, Media Relations
Ellen_Berlin@DFCI.HARVARD.EDU
Source: Celgene Corporation
© 2024 Canjex Publishing Ltd. All rights reserved.